Sign up to save your podcasts
Or
Share 30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 10 Control of Impurities (Organic, Inorganic, Residual Solvents) SUPPLEMENT
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 10 Control of Impurities (Organic, Inorganic, Residual Solvents) SUPPLEMENT
This podcast episode explores the fascinating differences between natural botanical extracts and their synthetic counterparts, with a focus on impurities. It delves into how the endocannabinoid system (ECS) interacts with these compounds and introduces the concept of polypharmacy - where multiple compounds work together synergistically. The discussion covers important aspects like variability in natural products, standardization challenges, and safety considerations, while highlighting how these "impurities" might actually be beneficial components that contribute to the overall therapeutic effects.
View all episodes
By Jim Mitchell and Google NotebookLMThis podcast episode explores the fascinating differences between natural botanical extracts and their synthetic counterparts, with a focus on impurities. It delves into how the endocannabinoid system (ECS) interacts with these compounds and introduces the concept of polypharmacy - where multiple compounds work together synergistically. The discussion covers important aspects like variability in natural products, standardization challenges, and safety considerations, while highlighting how these "impurities" might actually be beneficial components that contribute to the overall therapeutic effects.